TWSTTwist Bioscience Corp

Nasdaq twistbioscience.com


$ 44.18 $ 1.22 (2.84 %)    

Wednesday, 21-Aug-2024 15:59:49 EDT
QQQ $ 482.88 $ 2.24 (0.47 %)
DIA $ 408.91 $ 0.43 (0.11 %)
SPY $ 560.81 $ 1.92 (0.34 %)
TLT $ 98.72 $ 0.06 (0.06 %)
GLD $ 232.16 $ -0.31 (-0.13 %)
$ 44.13
$ 44.10 x 100
-- x --
-- - --
$ 14.42 - $ 60.90
416,860
na
2.57B
$ 1.81
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-02-2024 06-30-2024 10-Q
2 05-02-2024 03-31-2024 10-Q
3 02-02-2024 12-31-2023 10-Q
4 11-21-2023 09-30-2023 10-K
5 08-07-2023 06-30-2023 10-Q
6 05-08-2023 03-31-2023 10-Q
7 02-07-2023 12-31-2022 10-Q
8 11-28-2022 09-30-2022 10-K
9 08-08-2022 06-30-2022 10-Q
10 05-06-2022 03-31-2022 10-Q
11 02-09-2022 12-31-2021 10-Q
12 11-23-2021 09-30-2021 10-K
13 08-09-2021 06-30-2021 10-Q
14 05-07-2021 03-31-2021 10-Q
15 02-09-2021 12-31-2020 10-Q
16 11-27-2020 09-30-2020 10-K
17 08-12-2020 06-30-2020 10-Q
18 05-13-2020 03-31-2020 10-Q
19 02-10-2020 12-31-2019 10-Q
20 12-13-2019 09-30-2019 10-K
21 08-09-2019 06-30-2019 10-Q
22 05-02-2019 03-31-2019 10-Q
23 02-11-2019 12-31-2018 10-Q
24 12-20-2018 09-30-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 twist-bioscience-announces-the-expansion-of-its-dna-synthesis-offering-with-the-launch-of-gene-fragments-with-increased-lengths-ranging-from-18kb-to-50kb

Industry leading product available through Twist ecommerce platformTwist Gene Fragments now available up to 5.0kb in length wit...

 barclays-maintains-overweight-on-twist-bioscience-lowers-price-target-to-55

Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and lowers the price target from $6...

 jp-morgan-maintains-underweight-on-twist-bioscience-raises-price-target-to-35

JP Morgan analyst Tycho Peterson maintains Twist Bioscience (NASDAQ:TWST) with a Underweight and raises the price target fro...

 twist-bioscience-and-bitbiome-announced-the-launch-of-a-joint-transaminase-enzyme-screening-kit

Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthe...

 baird-maintains-outperform-on-twist-bioscience-raises-price-target-to-46

Baird analyst Catherine Ramsey maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and raises the price target from $...

 scorpion-capital-scorpionfund-posts-on-x-we-remain-short-twst-twist-bioscience-with-strong-conviction-that-it-is-a-zero-detailed-thoughts-on-monday-were-doing-a-fresh-intensive-round-of-research-which-we-may-publish-as-a-follow-up-to-our-nov-2022-short-report

https://x.com/ScorpionFund/status/1819408275474874573 

 twist-bioscience-beats-q3-earnings-forecast-plans-to-achieve-50-gross-margin-by-fiscal-year-2025

Twist Bioscience reported a Q3 adjusted EPS loss of $(0.70), surpassing the $(0.77) consensus. With a net loss of $85.6 million...

 twist-bioscience-expects-q4-2024-revenues-of-82m-83m-versus-prior-guidance-of-77m-80m-and-consensus-of-79602m

For the fourth quarter of fiscal year 2024, Twist provided the following financial guidance:Total revenue of approximately $82 ...

 twist-bioscience-expects-2024-revenues-of-310m-311m-versus-prior-guidance-of-300m-304m-and-consensus-of-303906m

For the full fiscal year 2024, Twist provided the following updated financial guidance:Total revenue is expected to be approxim...

 twist-bioscience-announces-clinical-progression-of-pure-biologics-antibody-candidate-discovered-using-twists-antibody-libraries

Pure Biologics' exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumorsTwist Bioscience ...

 cathie-wood-touts-palantir-coinbase-and-roku-as-arks-flagship-fund-shifts-focus-from-mag-6-amid-whiff-of-lower-interest-rates

In a recent letter to investors, Cathie Wood, the CEO of ARK Invest, highlighted the potential of the company's flagship fu...

 goldman-sachs-maintains-buy-on-twist-bioscience-raises-price-target-to-55

Goldman Sachs analyst Matthew Sykes maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $45...

 barclays-maintains-overweight-on-twist-bioscience-raises-price-target-to-60

Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and raises the price target from $4...

 td-cowen-maintains-buy-on-twist-bioscience-raises-price-target-to-65

TD Cowen analyst Steven Mah maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $55 to $65.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION